NEW YORK , May 18, 2026 /PRNewswire/ --
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin...
NEW YORK , May 11, 2026 /PRNewswire/ --
WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to...
NEW YORK , May 6, 2026 /PRNewswire/ --
Barchart Research What to Expect from IRON Earnings IRON Generated May 5, 2026 Current Price $67.59 EPS Estimate $$-1.55 Consensus Rating Strong Buy Average Move 2.79% Disc Medicine's Regulatory Path Forward...
Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 Updated data from Phase 2 study of DISC-0974 in patients with...
NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...
NEW YORK , April 30, 2026 /PRNewswire/ --